NCT06934343 Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data
| NCT ID | NCT06934343 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Utah |
| Condition | Non-small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 144,400 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 144,400 participants in total. It began in 2024-09-01 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treatment strategies for patients with advanced non-small cell lung cancer (aNSCLC). Rather than influencing regulatory decisions or clinical guidelines, the goal of this trial is to refine treatment selection among existing therapeutic options, ensuring that care is tailored to individual patient characteristics. Additionally, by generating real-world evidence, these findings will inform the design and implementation of future clinical trials. Importantly, the methodological advancements will establish a pipeline that extends beyond aNSCLC, facilitating the identification of optimal dynamic treatment regimes (DTRs) for other complex diseases.
Eligibility Criteria
Inclusion Criteria Subjects must meet all of the following eligibility criteria: * Diagnosed with advanced NSCLC between January 1, 2011, and June 30, 2024. * Follow-up available until December 31, 2024, with a minimum potential follow-up period of at least six months. Exclusion Criteria Subjects meeting any of the following criteria at baseline will be excluded: * Fewer than one day of follow-up post-initiation of first-line (1L) therapy. * Presence of a targetable mutation, including ALK, BRAF, EGFR, KRAS, or ROS1. * PD-L1 expression \<50% at baseline (restricted to patients with PD-L1 ≥50%). * First-line treatment limited to immunotherapy or chemoimmunotherapy (excluding other treatment regimens). * Patients receiving second-line (2L) treatment, including those enrolled in a clinical study.
Frequently Asked Questions
Who can join the NCT06934343 clinical trial?
This trial is open to participants of all sexes, studying Non-small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06934343 currently recruiting?
Yes, NCT06934343 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Utah to inquire about joining.
Where is the NCT06934343 trial being conducted?
This trial is being conducted at Salt Lake City, United States.
Who is sponsoring the NCT06934343 clinical trial?
NCT06934343 is sponsored by University of Utah. The trial plans to enroll 144,400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.